Scream Cream


PRP Therapy

Upto 68 to 75 percent woman has  sexual dissatisfaction. Only 2% of physician chart registers sexual dysfunction among woman.



Do you need this service?Assessment questions for Sexual Function

Rate your sexual satisfaction on a scale of

1-10, with 1 being dissatisfied all the time.


How often do you have sexual activity?

3/week   1/week   <1/week  never

Do you have pain with sexual Intercourse?

Yes-- No __


Have you had your hormone level checked?

Yes-- No __

Do you have a history of Sexual Abuse?


1. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281(6):537-544. Erratum in: JAMA. 1999;281(13):1174.

2. West SL, D’Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med. 2008;168(13):1441-1449.

3. North American Menopause Society. The role of testosterone therapy in postmenopausal women: position statement of the North American Menopause Society. Menopause. 2005;12(5):496-511.

4. Davis SR, Moreau M, Kroll R, et al; APHRODITE Study Team. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008;359(19):2005-2017.

5. Dimitrakakis C, Jones RA, Liu A, Bondy CA. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause. 2004;11(5):531-535.

6. Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med. 2009;6(9):2579-2590.

7. Panjari M, Davis SR. DHEA for postmenopausal women: a review of the evidence. Maturitas. 2010;66(2):172-179.

8. Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause. 2009;16(5):907-922.

9. Labrie F, Archer D, Bouchard C, et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause. 2009;16(5):923-931.

10. Panjari M, Davis SR. Vaginal DHEA to treat menopause related atrophy: a review of the evidence. Maturitas. 2011;70(1):22-25.

11. Duckiit K. Medical management of perimenopausal menorrhagia: an evidence-based approach. Menopause Int. 2007 Mar;13(1):14-8.

12. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006;(4):CD001500.

13. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause. 2012;19(3):257-271.

14. Osmanag˘aog˘lu MA, Atasaral T, Baltaci D, Bozkaya H. Effect of different preparations of hormone therapy on sexual dysfunction in naturally postmenopausal women. Climacteric. 2006;9(6):464-472.

15. Ziaei S, Moghasemi M, Faghihzadeh S. Comparative effects of conventional hormone replacement therapy and tibolone on climacteric symptoms and sexual dysfunction in postmenopausal women. Climacteric. 2010;13(2):147-156.

16. Formoso G, Perrone E, Maltoni S, et al. Short and long term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2012;2:CD008536.

17. Segraves RT, Clayton A, Croft H, et al. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J Clin Psychopharmacol 2004; 24:339.

18. DeBattista C, Solvason B, et al. A placebo-controlled, randomized, double-blind study of adjunctive buproprion sustained release in the treatment of SSRI-induced sexual dysfunction. J Clin Psychiatry. 2005 Jul;66(7):844-8.

19. Derogatis LR, Komer L. Treatment of hypoactive sexual desire disorder in the premenopausal women: efficacy of flibanserin in the VIOLET study. J Sex Med. 2012 Apr;9(4):1074-85.

20. Caruso S, Agnello C, et al. Placebo-controlled study on efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder. Urology. 2004 May;63(5):955-9.

21. Basson R, McInnes R, Smith MD, et al. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002; 11:367.

22. Ferguson DM, Hosmane B, Heiman JR. Randomized, placebo-controlled, double-blind, parallel design trial of the efficacy and safety of Zestra in women with mixed desire/interest/arousal/orgasm disorders. J Sex Marital Ther. 2010;36(1):66-86.

23. Ito TY, Trant AS, Polan ML. A double-blind placebo-controlled study of ArginMax, a nutritional supplement for enhancement of female sexual function. J Sex Marital Ther. 2001;27(5):541-549.

24. Davis AR, Castaño PM. Oral contraceptives and libido in women. Annu Rev Sex Res. 2004;15:297-320.

25. Schaffir J. Hormonal contraception and sexual desire: a critical review. J Sex Marital Ther. 2006;32(4):305-314.

26. Panzer C, Wise S, Fantini G, et al. Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction. J Sex Med. 2006;3(1):

27. Bradford A. Listening to placebo in clinical trials for female sexual dysfunction. J Sex Med. 2012 Oct 4. Epub ahead of print.

28. Bradford A, Meston CM. Placebo response in the treatment of women’s sexual dysfunctions: a review and commentary. J Sex Marital Ther. 2009;35(3):164-181.